SCHEMBL3245923

SCHEMBL3245923

CCCOc1cc(Cl)ccc1C(=O)NC(c1ccccc1)C(C)(C)N1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNLIP P16233 1/20 0.42
ADRB1 P08588 4/20 0.39
ADRB3 P13945 4/20 0.39
MET P08581 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 2/20 0.38
MITF O75030 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NLRP1 Q9C000 1/20 0.38
TP53 P04637 1/20 0.37
ITGB3 P05106 2/20 0.37
ITGA2B P08514 2/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
PKM P14618 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3241301 0.88 MEN1 (0.42) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL3238418 0.81 MEN1 (0.45) METMEN1KMT2AMAPTLMNA
SCHEMBL3239516 0.77 ALDH1A1 (0.41) MAPTSMN1; SMN2ITGB3ITGA2BALDH1A1
SCHEMBL3238718 0.76 P2RX7 (0.43) MAPTRAB9AALDH1A1
SCHEMBL3237736 0.75 KCNK3 (0.39) MEN1KMT2ALMNAALDH1A1SLC6A9
SCHEMBL3238547 0.75 SMN1; SMN2 (0.48) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL3236158 0.75 SLC6A9 (0.41) MEN1KMT2AMAPTLMNATP53
SCHEMBL3244636 0.75 THRB (0.43) PNLIPADRB1ADRB3MEN1KMT2A
SCHEMBL3241801 0.75 LMNA (0.40) MEN1KMT2ALMNAITGB3ITGA2B
SCHEMBL3238743 0.74 KMT2A (0.45) MEN1KMT2AMAPTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 PNLIP 3107/4885ADRB1 694/4885ADRB3 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.